NAMS Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
19.2M
+417.8%
3.7M
+21.7%
3.0M
+9400.0%
32.0K
-90.8%
348.0K
Cost of Revenue
0
0
0
0
0
Gross Profit
19.2M
+417.8%
3.7M
+21.7%
3.0M
+9400.0%
32.0K
-90.8%
348.0K
Operating Expenses
63.4M
-7.6%
68.6M
+11.6%
61.5M
-6.9%
66.0M
+19.0%
55.5M
R&D
39.4M
-5.6%
41.7M
+9.6%
38.0M
-1.5%
38.6M
+24.6%
31.0M
SG&A
24.0M
-10.8%
26.9M
+14.7%
23.5M
-14.5%
27.4M
+11.8%
24.5M
Operating Income
-44188000
+31.9%
-64864000
-11.0%
-58420000
+11.5%
-65980000
-19.7%
-55144000
EBITDA
-44121000
+31.9%
-64805000
-11.0%
-58358000
+11.5%
-65921000
-19.7%
-55080000
Net Income
-17389000
+72.9%
-64135000
-32.4%
-48441000
+35.3%
-74923000
-4.1%
-72005000
EPS (Basic)
$-0.14
+73.1%
$-0.52
-30.0%
$-0.40
+35.5%
$-0.62
-1.6%
$-0.61
EPS (Diluted)
$-0.14
+73.1%
$-0.52
-30.0%
$-0.40
+35.5%
$-0.62
-1.6%
$-0.61
Shares (Diluted)
124.1M
+0.6%
123.4M
+1.4%
121.7M
+1.4%
120.0M
+0.9%
119.0M
NewAmsterdam Pharma Company N.V. (NAMS) — Financials